Greece’s Drug Industry Warns of a Breaking Point

Greece’s pharmaceutical sector is sounding the alarm over what industry leaders describe as an unsustainable financing model, one that has quietly shifted the burden of public drug spending from the state onto the companies themselves, with patients increasingly caught in the middle.

In a resolution passed at the general assembly of the Hellenic Association of Pharmaceutical Companies (known by its Greek acronym, SFEE), industry representatives warned that mandatory rebates, known as clawbacks have now surpassed 58% on average in Greece. The clawbacks are a cost-containment mechanism, used across several EU member states, that requires drug makers to return a portion of their revenues to the state when pharmaceutical spending exceeds a predefined budget cap. That figure has been climbing at roughly 20% per year, and for the past four years, the industry’s net financial contribution to public drug coverage has exceeded that of the Greek government itself. SFEE described this as an unprecedented situation within the EU.

The numbers behind that claim are stark. Between 2019 and 2024, public funding for pharmaceutical expenditure grew at just 3.65%, while total drug spending in the country rose by 10.9%. The gap between the two has been filled almost entirely by the industry, through the clawback